Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 29, 2016 07:00 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical, Inc. Announces SPA Agreement with US FDA and Initiation of Phase III Wet AMD Clinical Program

NEW YORK, March 29, 2016 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (NASDAQ:OHRP), a clinical-stage biotechnology company developing novel therapies for ophthalmic diseases, today announced that...
March 02, 2016 14:45 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical to Present at Upcoming Investment Conferences

NEW YORK, March 02, 2016 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that Dr. Jason Slakter, Chief Executive...
February 09, 2016 16:01 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical Reports First Quarter 2016 Financial and Business Results

Conference Call Today at 5:00pm Eastern Time NEW YORK, Feb. 09, 2016 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today reported...
February 09, 2016 09:48 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical to Present at the LEERINK Partners 5th Annual Global Healthcare Conference in New York

NEW YORK, Feb. 09, 2016 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that Dr. Jason Slakter, Chief Executive...
February 03, 2016 08:00 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical to Announce First Quarter 2016 Financial Results on February 9

NEW YORK, Feb. 03, 2016 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that it will report financial results for...
December 10, 2015 16:01 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical Reports Fiscal Year 2015 Financial and Business Results

OHR-102 Phase 3 Program in Wet-AMD to be Initiated Upon Completion of SPA; Enroll Patients in Q1 2016 Conference Call and Webcast with Slides, Today at 5:00pm Eastern Time NEW YORK, Dec. 10,...
December 08, 2015 08:00 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical to Report Fiscal 2015 Financial Results on Thursday, December 10

NEW YORK, Dec. 8, 2015 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that it will report financial results for fiscal...
December 03, 2015 08:00 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical Announces Positive Preclinical Data in SKS Sustained Release Ocular Program

NEW YORK, Dec. 3, 2015 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced positive results from a preclinical study...
November 16, 2015 08:00 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical Presents New Data From OHR-102 Phase II IMPACT Study in Wet-AMD at American Academy of Ophthalmology Annual Meeting

Occult CNV Size in Wet-AMD is Predictive of Success of OHR-102 Combination Therapy Results Drive Patient Selection and Design for Phase 3 Program NEW YORK, Nov. 16, 2015 (GLOBE NEWSWIRE) -- Ohr...
November 12, 2015 08:00 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical Announces Submission of a Special Protocol Assessment and Upcoming Presentation on OHR-102 at American Academy of Ophthalmology

NEW YORK, Nov. 12, 2015 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced the company has submitted a Special Protocol...